Glucose-dependent insulinotropic polypeptide vs Tirzepatide
The second incretin, with distinct adipose and CNS biology. A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Glucose-dependent insulinotropic polypeptide GIP | Tirzepatide | |
|---|---|---|
| Also known as | — | Mounjaro, Zepbound |
| Type | Endogenous | Analog |
| Evidence | Established | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Incretin peptide (42 aa) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor | GIP receptor (GIPR), a class B GPCR | GIP receptor + GLP-1 receptor |
| Molecular weight | ~4,983.6 Da | ~4,813.5 Da |
| Half-life | ||
| Based on | Native hormone | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Glucose-dependent insulinotropic polypeptide and Tirzepatide?
- Glucose-dependent insulinotropic polypeptide is an endogenous hormone; Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide. Glucose-dependent insulinotropic polypeptide signals at GIP receptor (GIPR), a class B GPCR; Tirzepatide signals at GIP receptor + GLP-1 receptor.
- How do the half-lives of GIP and Tirzepatide compare?
- The reported circulating half-life of Glucose-dependent insulinotropic polypeptide is ~5–7 min (native; DPP-4); Tirzepatide is ~5 days (~120 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tirzepatide vs Glucose-dependent insulinotropic polypeptide. Or open the interactive comparison tool to add more molecules.